222MO Exploratory analysis of participants without pathological complete response (pCR) in the KEYNOTE-671 study of perioperative pembrolizumab (pembro) in early-stage NSCLC after 5 years of follow-up

ESMO Open 2026 Open access

Read full text
Authors: M. Reck, C. Grohe, G. Vogel, J. Bosch-Barrera, Tõnu Vanakesa, F. Guisier, Ingel Demedts, Martin Faehling, G. Lo Russo, E. Levchenko, G. Ursol, O. Voitko
+4 more E. Jensen, S. Keller, Ayman Samkari, H. Wakelee
DOI: 10.1016/j.esmoop.2026.106530
Cited by: 3

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Colorectal and Anal Carcinomas Lung Cancer Diagnosis and Treatment

Publication details

Journal / source
ESMO Open
Publisher
Elsevier BV
Volume
11
Pages
106530–106530
Publication date
17 March 2026
Language
EN